Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Biogen Idec Ma Inc.

Millenium Pharmaceuticals, Inc.

Timothy Raymond Chan

Gnanasambandam Kumaravel

Brian T Hopkins

Tracy J Jenkins

Joseph P Lyssikatos

Kevin Guckian

Lihong Sun

Bin Ma

Patrick R Conlon

Lei Zhang

Andrew S Thompson

Jermaine Thomas

Ross A Miller

Michael J Humora

Hua Miao

Xianglin Shi

Xiongwei Cai

Kevin Koch

Edward Yin-Shiang Lin

Brian Stuart Lucas

Irina Leaf

Jeremy Duffield

Robert Meissner

Arthur G Taveras

Zhili Xin

Deping Wang

Daniel M Scott

Wen-Cherng Lee

Daniel A Erlanson

Hairuo Peng

Joseph Arndt

Jeffery Vessels

Kurt D Van Vloten

Jianhua Chao

Kevin Lewis Otipoby

Jeffrey Vessels

Edward Yin Shiang Lin

Nathan Genung

J Michael Macphee

Daniel Erlanson

Michael J Macphee

Andrea Bertolotti-Ciarlet

Charles Jewell

Michael Humora

Andrew Thompson

Edward Lin

Kurt Van Vloten

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Biaryl inhibitors of Bruton's tyrosine kinase

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease. 

IRAK4 inhibiting agents

Biaryl inhibitors of Bruton'S tyrosine kinase

Pyrimidinyl tyrosine kinase inhibitors

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Biaryl bruton's tyrosine kinase inhibitors

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

Inhibitors of Bruton's tyrosine kinase

Biaryl inhibitors of bruton's tyrosine kinase

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Heterocyclic compounds useful as PDK1 inhibitors

Compounds of formula (I) wherein: X is &#x2014;O&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;CH&#x2014;, or &#x2014;NR&#x2014;, wherein r is 0, 1, or 2; X, X, and Xare each independently CRor N; one of Xor Xis C and is attached by a single bond to -L-, and the other is CRor N, provided that no more than three of X, X, X, X or Xare N; Ring A is monocyclic Cscycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or O; wherein Ring A is further optionally substituted with from 1 to 3 R; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, &#x2014;O&#x2014;, &#x2014;NR&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;CH&#x2014;, or &#x2014;C(O)&#x2014;, wherein n is 0, 1, or 2; 1 2 Lis an Calkylene, Ccycloalkylene, &#x2014;CH-L-, or a 3- to 8-membered heterocyclylene comprising 1 to 5; Ris Calkyl or a monocyclic Ccycloalkyl; wherein said Ccycloalkyl is substituted with at least one Rand may be optionally substituted with from 1 to 5 additional Rsubstituents, wherein Rfor each occurrence is independently selected; and Ris &#x2014;C(O)OR, &#x2014;C(O)N(R)&#x2014;S(O)R, &#x2014;S(O)OR, &#x2014;C(O)NHC(O)R, &#x2014;Si(O)OH, &#x2014;B(OH), &#x2014;N(R)S(O)R, &#x2014;S(O)N(R), &#x2014;O&#x2014;P(O)(OR), or &#x2014;P(O)(OR), &#x2014;CN, &#x2014;S(O)NHC(O)R, &#x2014;C(O)NHS(O)R3, &#x2014;C(O)NHOH, &#x2014;C(O)NHCN, &#x2014;CH(CF)OH, &#x2014;C(CF)OH, or a selected heteroaryl or heterocyclyl; and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). 

S1P and/or ATX modulating agents

Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

Growing community of inventors

Newton, MA, United States of America

Timothy Raymond Chan